Trial Profile
Characterization of T-Cell Response in Subjects Previously Treated With JNJ-54861911 (Atabecestat)
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Atabecestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 27 Aug 2018 Status changed from recruiting to completed.
- 19 Jul 2018 New trial record